These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 9363187)

  • 1. Is gene therapy in cystic fibrosis a realistic expectation?
    McElvaney NG
    Curr Opin Pulm Med; 1996 Nov; 2(6):466-71. PubMed ID: 9363187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene transfer to freshly isolated human respiratory epithelial cells in vitro using a replication-deficient adenovirus containing the human cystic fibrosis transmembrane conductance regulator cDNA.
    Rosenfeld MA; Chu CS; Seth P; Danel C; Banks T; Yoneyama K; Yoshimura K; Crystal RG
    Hum Gene Ther; 1994 Mar; 5(3):331-42. PubMed ID: 7517189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis.
    Zabner J; Ramsey BW; Meeker DP; Aitken ML; Balfour RP; Gibson RL; Launspach J; Moscicki RA; Richards SM; Standaert TA
    J Clin Invest; 1996 Mar; 97(6):1504-11. PubMed ID: 8617884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
    Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP
    Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector.
    Hay JG; McElvaney NG; Herena J; Crystal RG
    Hum Gene Ther; 1995 Nov; 6(11):1487-96. PubMed ID: 8573621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for the respiratory manifestations of cystic fibrosis.
    Korst RJ; McElvaney NG; Chu CS; Rosenfeld MA; Mastrangeli A; Hay J; Brody SL; Eissa NT; Danel C; Jaffe HA
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S75-87. PubMed ID: 7533609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung.
    Crystal RG; Jaffe A; Brody S; Mastrangeli A; McElvaney NG; Rosenfeld M; Chu CS; Danel C; Hay J; Eissa T
    Hum Gene Ther; 1995 May; 6(5):643-66. PubMed ID: 7578401
    [No Abstract]   [Full Text] [Related]  

  • 8. Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways.
    Zhang Y; Jiang Q; Dudus L; Yankaskas JR; Engelhardt JF
    Hum Gene Ther; 1998 Mar; 9(5):635-48. PubMed ID: 9551612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis.
    Crystal RG; Mastrangeli A; Sanders A; Cooke J; King T; Gilbert F; Henschke C; Pascal W; Herena J; Harvey BG
    Hum Gene Ther; 1995 May; 6(5):667-703. PubMed ID: 7578402
    [No Abstract]   [Full Text] [Related]  

  • 10. Toward cystic fibrosis gene therapy.
    Wagner JA; Gardner P
    Annu Rev Med; 1997; 48():203-16. PubMed ID: 9046956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.
    Wagner JA; Messner AH; Moran ML; Daifuku R; Kouyama K; Desch JK; Manley S; Norbash AM; Conrad CK; Friborg S; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P
    Laryngoscope; 1999 Feb; 109(2 Pt 1):266-74. PubMed ID: 10890777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis.
    Zuckerman JB; Robinson CB; McCoy KS; Shell R; Sferra TJ; Chirmule N; Magosin SA; Propert KJ; Brown-Parr EC; Hughes JV; Tazelaar J; Baker C; Goldman MJ; Wilson JM
    Hum Gene Ther; 1999 Dec; 10(18):2973-85. PubMed ID: 10609658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung.
    Yei S; Mittereder N; Wert S; Whitsett JA; Wilmott RW; Trapnell BC
    Hum Gene Ther; 1994 Jun; 5(6):731-44. PubMed ID: 7948135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.
    Knowles MR; Hohneker KW; Zhou Z; Olsen JC; Noah TL; Hu PC; Leigh MW; Engelhardt JF; Edwards LJ; Jones KR
    N Engl J Med; 1995 Sep; 333(13):823-31. PubMed ID: 7544439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia.
    Granio O; Ashbourne Excoffon KJ; Henning P; Melin P; Norez C; Gonzalez G; Karp PH; Magnusson MK; Habib N; Lindholm L; Becq F; Boulanger P; Zabner J; Hong SS
    Hum Gene Ther; 2010 Mar; 21(3):251-69. PubMed ID: 19788389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.
    Porteous DJ; Dorin JR; McLachlan G; Davidson-Smith H; Davidson H; Stevenson BJ; Carothers AD; Wallace WA; Moralee S; Hoenes C; Kallmeyer G; Michaelis U; Naujoks K; Ho LP; Samways JM; Imrie M; Greening AP; Innes JA
    Gene Ther; 1997 Mar; 4(3):210-8. PubMed ID: 9135734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill.
    Boucher RC; Knowles MR; Johnson LG; Olsen JC; Pickles R; Wilson JM; Engelhardt J; Yang Y; Grossman M
    Hum Gene Ther; 1994 May; 5(5):615-39. PubMed ID: 7519885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for cystic fibrosis by means of aerosol.
    Rochat T; Morris MA
    J Aerosol Med; 2002; 15(2):229-35. PubMed ID: 12184873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA-CFTR in the respiratory tractus in patients with cystic fibrosis].
    Bellon G; Calmard L; Thouvenot D; Levrey H; Jagneaux V; Poitevin F; Malcus C; Accart N; Séné C; Layani MP; Aymard M; Bienvenu J; Courtney M; Döring G; Gilly B; Gilly R; Lamy D; Morel Y; Paulin C; Perraud F; Rodillon L; So S; Touraine F; Schatz C; Pavirani A
    C R Seances Soc Biol Fil; 1996; 190(1):109-42. PubMed ID: 8881273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.
    Crystal RG; McElvaney NG; Rosenfeld MA; Chu CS; Mastrangeli A; Hay JG; Brody SL; Jaffe HA; Eissa NT; Danel C
    Nat Genet; 1994 Sep; 8(1):42-51. PubMed ID: 7527271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.